There's always time to prevent a mistake.

Brands will lean on AI-powered concierges to elevate offline events and improve ROI. Follow Ai news and artificial intelligence news for expert updates. Act now and learn more.

#AIEventMarketing
#AIInsights2026
#EventTechInnovation
#aitechnews

Read More:https://ai-techpark.com/event-marketing-in-2026/

Global Enoxaparin Sodium Market (2025–2032): Growing at 7.7% CAGR, Driven by Rising Thrombotic Disorders & Expanding Clinical Applications
Global Enoxaparin Sodium Market is experiencing strong growth, expanding at a 7.7% CAGR from 2025 to 2032. Valued at USD 3,027 million in 2024, the market is set to reach USD 5,111 million by 2032, driven by rising global incidence of thrombotic disorders, increasing surgical procedures, and growing adoption in acute coronary syndrome management.Enoxaparin Sodium—a widely used low molecular weight heparin (LMWH)—plays a vital role in preventing and treating DVT, PE, maintaining catheter patency during dialysis, and supporting thromboprophylaxis in oncology and pregnancy-related complications.

How Predictive Analytics for Dropout Prevention is Transforming Education

read more : https://bi-journal.com/how-predictive-analytics-for-dropout-prevention-is-transforming-education/

#PredictiveAnalytics #Education #BIJournal #BIJournalnews #BusinessInsightsarticles #BIJournalinterview

Global Enoxaparin Sodium Market: USD 3,027 Million in 2024 to USD 5,111 Million by 2032, Growing at a CAGR of 7.7%
Global Enoxaparin Sodium Market is experiencing strong growth driven by rising cases of thrombotic disorders, increasing surgical procedures, and expanding use in acute coronary syndrome (ACS) management. Enoxaparin Sodium, a widely used low molecular weight heparin (LMWH), offers predictable anticoagulation, reduced monitoring needs, and enhanced safety over traditional heparin. Its applications span DVT and PE prevention, pregnancy-related thrombophilia, oncology-related VTE, and hemodialysis care. Market expansion is supported by improving healthcare infrastructure, growing adoption of standardized thromboprophylaxis protocols, and rising awareness in emerging regions. Despite biosimilar competition and regulatory challenges, opportunities remain strong across developing markets and innovative delivery systems